Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-6901
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events ; day:26 ; month:12 ; year:2016 ; pages:1-7
Drugs in R & D ; (26.12.2016), 1-7
- Schlagwort
-
Orthopädie
- Urheber
-
Wakabayashi, Hiroki
- Beteiligte Personen und Organisationen
-
Inada, Hitoshi
Nishioka, Yosuke
Hasegawa, Masahiro
Nishioka, Kusuki
Sudo, Akihiro
SpringerLink (Online service)
- DOI
-
10.1007/s40268-016-0162-8
- URN
-
urn:nbn:de:1111-201701241581
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wakabayashi, Hiroki
- Inada, Hitoshi
- Nishioka, Yosuke
- Hasegawa, Masahiro
- Nishioka, Kusuki
- Sudo, Akihiro
- SpringerLink (Online service)
Ähnliche Objekte (12)
Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration
Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
Potential Cost Savings by Switching from Subcutaneous to Intralymphatic Insect Venom Immunotherapy
Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment
Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
Circulating tumour necrosis factor-α bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment
Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis
Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration
Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
Potential Cost Savings by Switching from Subcutaneous to Intralymphatic Insect Venom Immunotherapy
Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment
Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
Circulating tumour necrosis factor-α bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment
Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis
Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration
Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
Potential Cost Savings by Switching from Subcutaneous to Intralymphatic Insect Venom Immunotherapy
Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment
Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
Circulating tumour necrosis factor-α bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment